abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) was the target of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 58,626 shares, an increase of 217.9% from the July 30th total of 18,442 shares. Based on an average trading volume of 149,213 shares, the short-interest ratio is presently 0.4 days. Currently, 0.2% of the shares of the company are sold short.

abrdn Life Sciences Investors Stock Up 0.1%

Shares of HQL stock traded up $0.01 during trading hours on Thursday, hitting $21.55. The company’s stock had a trading volume of 92,299 shares, compared to its average volume of 129,278. abrdn Life Sciences Investors has a 12-month low of $13.82 and a 12-month high of $22.67. The company has a 50 day moving average of $20.14 and a 200 day moving average of $18.16.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be given a dividend of $0.62 per share. The ex-dividend date is Monday, August 24th. This represents a $2.48 dividend on an annualized basis and a yield of 11.5%.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. raised its stake in shares of abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after buying an additional 1,529 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of abrdn Life Sciences Investors by 187.8% in the fourth quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after buying an additional 4,593 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of abrdn Life Sciences Investors in the fourth quarter worth about $177,000. Evolve Private Wealth LLC acquired a new stake in abrdn Life Sciences Investors during the fourth quarter worth about $199,000. Finally, Independent Financial Group LLC acquired a new stake in abrdn Life Sciences Investors during the first quarter worth about $211,000. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.